Tolterodine detailed information

Jump to navigation Jump to search
Tolterodine detailed information
File:Tolterodine.png
Clinical data
ATC code
Pharmacokinetic data
Bioavailability77%
Protein bindingApproximately 96.3%.
Elimination half-life1.9-3.7 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H31NO
Molar mass325.488 g/mol

Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. It is sold under the trade name Detrol.

Pharmacology

Tolterodine acts on M2 and M3 subtypes of muscarinic receptors whereas most antimuscarinic treatments for overactive bladder only act on M3 receptors making them more selective.

Tolterodine, although it acts on two types of receptors, has fewer side effects than other antimuscarinics eg. oxybutynin (which is selective for M3 only) as tolterodine targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are fewer side effects.

Side effects

Known Side Effects:

Reports of Patients’ Experiences Since Detrol Became Available:

The following reactions have been reported in patients who have taken Detrol since it has become available:

Contraindications Not to be used in patients with Myasthenia Gravis and Angle Closure Glaucoma

External links


Template:Pharma-stub Template:WikiDoc Sources